Gilgamesh managed to overcome the issue of functional unblinding in the study, an obstacle experienced by the psychedelic ...

Long-term, heavy ketamine use is associated with memory problems, depression and anxiety. The drug may also cause gastrointestinal problems, abdominal pain popularly known as “k-cramps” and uropathy, ...

Patients were assigned to the esketamine or control group based on whether they received a subanaesthetic dose of esketamine. Primary and secondary outcome measures The primary outcome was extubation ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Both esketamine and dexmedetomidine have been individually demonstrated to have the potential to enhance postoperative sleep quality. However, the effectiveness of mini-dose esketamine–dexmedetomidine ...

Results from the phase 2b trial are due later next year and according to Compass a single dose of COMP360 ... with Johnson & Johnson’s Spravato (esketamine) and a combination of olanzapine ...

In the new trial, called Study 501, a once-daily oral dose of Caplyta or a matched placebo ... for its nasal spray antidepressant Spravato (esketamine) in 2019 for treatment-resistant depression ...

Objective Ketamine and esketamine have both shown significant antidepressant ... Two more recent studies have analyzed this relationship in multiple-dose treatments. Wlodarczyk et al. 37 found no ...

Purpose: This study aims to validate the efficacy and safety of combining different doses of esketamine with propofol, remifentanil, and dexmedetomidine in spinal surgery under intra-operative ...

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company developing innovative, best-in-class new chemical entities (NCEs) that tran ...

Relief Mental Health, an award-winning outpatient provider of innovative mental health services, proudly announces the ...

Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg.